More Competition Coming To Cushing's Market

FDA Reviewing Strongbridge's Recorlev

 
• By Kevin Grogan

Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space

pituitary
In people with Cushing’s, high cortisol levels are triggered by a tumor in the pituitary gland • Source: Alamy

More from Rare Diseases

More from Scrip